Biolitec, Inc. v. Angiodynamics, Inc.

581 F. Supp. 2d 152, 2008 U.S. Dist. LEXIS 77826, 2008 WL 4446602
CourtDistrict Court, D. Massachusetts
DecidedSeptember 30, 2008
DocketC.A. 08-30011-MAP
StatusPublished
Cited by2 cases

This text of 581 F. Supp. 2d 152 (Biolitec, Inc. v. Angiodynamics, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Biolitec, Inc. v. Angiodynamics, Inc., 581 F. Supp. 2d 152, 2008 U.S. Dist. LEXIS 77826, 2008 WL 4446602 (D. Mass. 2008).

Opinion

MEMORANDUM AND ORDER RE: REPORT AND RECOMMENDATION WITH REGARD TO DEFENDANT’S MOTION TO DISMISS

(Dkt. Nos. 4 & 11)

PONSOR, District Judge.

In this declaratory and breach of contract action, Plaintiff seeks to recover funds he allegedly expended in helping defend Defendant in a patent infringement action. Defendant filed a Motion to Dismiss for failure to state a claim; it also moved for transfer of the case to the Northern District of New York if dismissal were not proper.

*153 Defendant’s motion was referred to Chief Magistrate Judge Kenneth P. Nei-man for report and recommendation. On September 11, 2008, Judge Neiman issued his Report and Recommendation, to the effect that Defendant’s Motion to Dismiss should be denied, but the motion to transfer the case should be allowed. His Report and Recommendation contained a footnote at 14 n. 5 warning the parties that any objection would have to be filed within ten days. No such objection has been filed. In view of the fact that both parties are represented by sophisticated counsel, the court must conclude that, in fact, there is no objection to the transfer of this case to the Northern District of New York.

In addition to the lack of any objection, the discussion set forth in the Report and Recommendation regarding transfer is entirely persuasive. See Docket No. 11 at 10-12.

In sum, upon de novo review, the court hereby ADOPTS the Report and Recommendation (Dkt. No. 11), both based upon the lack of objection and upon the inherent meritoriousness of the recommended ruling.

For these reasons, the court hereby DENIES Defendant’s Motion to Dismiss (Dkt. No. 4) but ALLOWS the motion to transfer the case to the Northern District of New York. The clerk is ordered to take whatever action is necessary to assure that this case is transferred.

It is So Ordered.

REPORT AND RECOMMENDATION WITH REGARD TO DEFENDANT’S MOTION TO DISMISS (Document No. 4)

NEIMAN, Chief United States Magistrate Judge.

This is a declaratory judgment and breach of contract action in which Biolitec, Inc. (“Plaintiff’) seeks to recover from An-gioDynamics, Inc. (“Defendant”) $1.6 million that it expended in helping defend Defendant in a patent infringement suit. Arguing that Plaintiffs complaint fails to state claims upon which relief may be granted, Defendant has moved to dismiss it pursuant to Fed.R.Civ.P. 12(b)(6). Defendant also asserts that the complaint should be dismissed — or transferred to the United States District Court for the Northern District of New York — because there is a previously-filed action there involving the same parties and the same underlying transaction (hereinafter “the New York action”). Defendant’s motion has been referred to this court for a report and recommendation. See 28 U.S.C. § 636(b)(1)(B). For the following reasons, the court will recommend that Defendant’s motion be allowed, but only to the extent that it seeks a transfer to the Northern District of New York.

I. Factual Background

The following factual allegations come from Plaintiffs complaint and are stated in a light most favorable to it. See Stanton v. Metro Corp., 438 F.3d 119, 123-24 (1st Cir.2006). On April 1, 2002, Plaintiff and Defendant entered into a Supply and Distribution Agreement (“SDA”), pursuant to which Plaintiff agreed to sell Defendant certain laser and fiber products. (Complaint ¶ 4, Ex. A.) In November of 2003, another company, Diomed, Inc. (“Diomed”), sued Defendant for patent infringement. (Id. ¶ 5.) One basis of that lawsuit involved Defendant’s sale of certain products that incorporated and modified the products that Plaintiff had sold to Defendant. (Id.)

Sections 7.2, 9.1 and 9.2 of the SDA discussed, as follows, the parties’ obligations with respect to potential infringement allegations — such as those brought by Diomed — as well as the parties’ indemnification rights:

*154 7.2 Infringement of Third Party Patents and Rights.... If a third party asserts that a patent or other proprietary right owned by it is infringed by the manufacture, marketing, sale, distribution or use of a Product, the party against whom such a claim was asserted shall provide the other party with notice of such claim within fifteen (15) days. BIOLITEC agrees to undertake the sole and complete defense, at its sole cost and expense, of any such claim through counsel of its choice and control the settlement of any such claim.... If BIOLITEC fails to take such action, AngioDynamics shall be entitled to do so and BIOLITEC shall promptly reimburse AngioDynamics for pre-agreed upon expenses it incurs, including without limitation reasonable attorney’s fees.
9.1 Indemnification by BIOLITEC. BIOLITEC agrees to indemnify and hold AngioDynamics harmless from and against any and all Loss that AngioDy-namics may incur to the extent that such Loss arises out of or results from (i) a breach of any representation or warranty or agreement given in this Agreement by BIOLITEC, or (ii) the injury, illness or death of any person which arises out of or relates to the manufacture or the design of Products.
9.2 Indemnification by AngioDynam-ics. AngioDynamics agrees to indemnify and hold BIOLITEC harmless from and against any and all Loss that BIOL-ITEC may incur to the extent that such Loss arises out of or results from (i) the unlawful sale, promotion and distribution of the Products by AngioDynamics in the Territory, (ii) any unauthorized modification or alteration made by An-gioDynamics to the Products, (iii) the improper sterilization or labeling of the Products, (iv) a breach of any representation made or warranty given in this Agreement by AngioDynamics, (v) mishandling of fibers during unpacking and repackaging of bulk fibers delivered to AngioDynamics for the purpose of putting into their kits, or (vi) the design of a product solely by AngioDynamics.

(Complaint, Ex. A.) At or around the time that Diomed commenced its action, Defendant made a demand for indemnification upon Plaintiff. (Complaint ¶ 10.) Although Plaintiff refused this demand, the parties entered into a Joint Defense Agreement (“JDA”) dated November 24, 2003. (Id. ¶¶ 11,12.)

Alleging that it had reserved its rights with respect to its indemnity obligations, Plaintiff contributed $1.6 million to Defendant’s defense in the Diomed litigation. (Id. ¶¶ 12-14.) 1 On September 27, 2007, Plaintiff demanded that Defendant reimburse this $1.6 million in defense costs, a demand Defendant has refused. (Id. ¶¶ 15, 16.)

Plaintiffs complaint contains four counts. Count I seeks a judgment declaring, pursuant to 28 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Quality One Wireless, LLC v. Goldie Group, LLC
37 F. Supp. 3d 536 (D. Massachusetts, 2014)
EMC Corp. v. Parallel Iron, LLC
914 F. Supp. 2d 125 (D. Massachusetts, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
581 F. Supp. 2d 152, 2008 U.S. Dist. LEXIS 77826, 2008 WL 4446602, Counsel Stack Legal Research, https://law.counselstack.com/opinion/biolitec-inc-v-angiodynamics-inc-mad-2008.